BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 3018478)

  • 1. Characterization of the binding of [3H]-(+/-)-L-364,718: a new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors.
    Chang RS; Lotti VJ; Chen TB; Kunkel KA
    Mol Pharmacol; 1986 Sep; 30(3):212-7. PubMed ID: 3018478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand.
    Chang RS; Chen TB; Bock MG; Freidinger RM; Chen R; Rosegay A; Lotti VJ
    Mol Pharmacol; 1989 Jun; 35(6):803-8. PubMed ID: 2733696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the binding of [3H]L-158,809: a new potent and selective nonpeptide angiotensin II receptor (AT1) antagonist radioligand.
    Chen TB; Lotti VJ; Chang RS
    Mol Pharmacol; 1992 Dec; 42(6):1077-82. PubMed ID: 1480133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3H]pBC 264, a suitable probe for studying cholecystokinin-B receptors: binding characteristics in rodent brains and comparison with [3H]SNF 8702.
    Durieux C; Ruiz-Gayo M; Corringer PJ; Bergeron F; Ducos B; Roques BP
    Mol Pharmacol; 1992 Jun; 41(6):1089-95. PubMed ID: 1614411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
    Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of [3H](+/-)L-364,718 binding to solubilized cholecystokinin (CCK) receptors of rat pancreas.
    Chang RS; Lotti VJ; Chen TB
    Biochem Pharmacol; 1987 May; 36(10):1709-14. PubMed ID: 3593394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.
    Chang RS; Lotti VJ
    Proc Natl Acad Sci U S A; 1986 Jul; 83(13):4923-6. PubMed ID: 3014520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor.
    Poirot SS; Escrieut C; Dufresne M; Martinez J; Bouisson M; Vaysse N; Fourmy D
    Mol Pharmacol; 1994 Apr; 45(4):599-607. PubMed ID: 8183238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type-A cholecystokinin binding sites in cow brain: characterization using (-)-[3H]L364718 membrane binding assays.
    Barrett RW; Steffey ME; Wolfram CA
    Mol Pharmacol; 1989 Aug; 36(2):285-90. PubMed ID: 2770704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]SR 48692, the first nonpeptide neurotensin antagonist radioligand: characterization of binding properties and evidence for distinct agonist and antagonist binding domains on the rat neurotensin receptor.
    Labbé-Jullié C; Botto JM; Mas MV; Chabry J; Mazella J; Vincent JP; Gully D; Maffrand JP; Kitabgi P
    Mol Pharmacol; 1995 May; 47(5):1050-6. PubMed ID: 7746272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type-A cholecystokinin receptors in CHP212 neuroblastoma cells: evidence for association with G protein and activation of phosphoinositide hydrolysis.
    Barrett RW; Steffey ME; Wolfram CA
    Mol Pharmacol; 1989 Apr; 35(4):394-400. PubMed ID: 2539554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist.
    Lotti VJ; Pendleton RG; Gould RJ; Hanson HM; Chang RS; Clineschmidt BV
    J Pharmacol Exp Ther; 1987 Apr; 241(1):103-9. PubMed ID: 2437282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and pharmacological profiles of loxiglumide, a novel cholecystokinin-A receptor antagonist.
    Fukamizu Y; Nakajima T; Kimura K; Kanda H; Fujii M; Saito T; Kasai H
    Arzneimittelforschung; 1998 Jan; 48(1):58-64. PubMed ID: 9522034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated ileum longitudinal muscle myenteric plexus.
    Dal Forno G; Pietra C; Urciuoli M; van Amsterdam FT; Toson G; Gaviraghi G; Trist D
    J Pharmacol Exp Ther; 1992 Jun; 261(3):1056-63. PubMed ID: 1602372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of cholecystokinin receptors and messenger RNA expression in rat pancreas: evidence for expression of cholecystokinin-A receptors but not cholecystokinin-B (gastrin) receptors.
    Zhou W; Povoski SP; Bell RH
    J Surg Res; 1995 Mar; 58(3):281-9. PubMed ID: 7533864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine 197 of the cholecystokinin-A receptor binding site interacts with the sulfate of the peptide agonist cholecystokinin.
    Gigoux V; Maigret B; Escrieut C; Silvente-Poirot S; Bouisson M; Fehrentz JA; Moroder L; Gully D; Martinez J; Vaysse N; Fourmy AD
    Protein Sci; 1999 Nov; 8(11):2347-54. PubMed ID: 10595537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.